Search Results for: KDR

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel KIT KIT proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Regulation of KIT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Dasatinib-resistant KIT mutants
  • Imatinib-resistant KIT mutants
  • KIT mutants bind TKIs
  • Masitinib-resistant KIT mutants
  • Nilotinib-resistant KIT mutants
  • Regorafenib-resistant KIT mutants
  • Signaling by kinase domain mutants of KIT
  • Sunitinib-resistant KIT mutants
  • Signaling by juxtamembrane domain KIT mutants
  • Sorafenib-resistant KIT mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by extracellular domain mutants of KIT
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • Phosphonotyrosine
  • Nilotinib
  • XL820
  • OSI-930
  • ABT-869
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Ancestim
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Pexidartinib
  • Ripretinib
  • Avapritinib
  • Piebaldism
  • Acute myeloid leukemia (AML)
Novel CACNA1S calcium voltage-gated channel subunit alpha1 S
  • NCAM1 interactions
  • Ergocalciferol
  • Enflurane
  • Ranolazine
  • Phenytoin
  • Isradipine
  • Topiramate
  • Nimodipine
  • Nisoldipine
  • Spironolactone
  • Cinnarizine
  • Magnesium sulfate
  • Levomenthol
  • Ethanol
  • Felodipine
  • Nitrendipine
  • Miconazole
  • Nifedipine
  • Amiodarone
  • Mibefradil
  • Dronedarone
  • Clevidipine
  • Nilvadipine
  • Trimebutine
  • Pinaverium
  • Aranidipine
  • Benidipine
  • Cilnidipine
  • Lacidipine
  • Manidipine
  • Butamben
  • Bioallethrin
  • Bioallethrin
  • Fish oil
  • Hypokalemic periodic paralysis (HypoPP)
Novel ALB albumin
  • Platelet degranulation
  • Recycling of bile acids and salts
  • Heme biosynthesis
  • Heme degradation
  • Scavenging of heme from plasma
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Transport of organic anions
  • Post-translational protein phosphorylation
  • HDL remodeling
  • Amsacrine
  • Cefotaxime
  • Pyridostigmine
  • Phenol
  • Norelgestromin
  • Aniline
  • Guaiacol
  • Artenimol
  • Silver
  • Patent Blue
Novel CHIC2 cysteine rich hydrophobic domain 2
Novel GSTA2 glutathione S-transferase alpha 2
  • Glutathione conjugation
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • Glutathione
  • Chloroquine
  • Glutathione disulfide
Novel SHOX2 short stature homeobox 2
Novel SRP72 signal recognition particle 72
  • SRP-dependent cotranslational protein targeting to membrane
  • SRP-dependent cotranslational protein targeting to membrane
Novel UTP3 UTP3 small subunit processome component
  • rRNA modification in the nucleus and cytosol
  • Major pathway of rRNA processing in the nucleolus and cytosol
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Urea
  • Gastric cancer
  • Colorectal cancer
  • Endometrial Cancer
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Thyroid cancer
  • Hepatocellular carcinoma
ATR ATR serine/threonine kinase
  • Meiotic synapsis
  • Activation of ATR in response to replication stress
  • Regulation of HSF1-mediated heat shock response
  • HDR through Single Strand Annealing (SSA)
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Fanconi Anemia Pathway
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Alveolar rhabdomyosarcoma
  • Seckel syndrome
COL18A1 collagen type XVIII alpha 1 chain
  • Collagen degradation
  • Activation of Matrix Metalloproteinases
  • Collagen biosynthesis and modifying enzymes
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Laminin interactions
  • Collagen chain trimerization
  • Vitreoretinal degeneration, including: Stickler syndrome type I (STL1); Stickler syndrome type II (STL2); Snowflake vitreoretinal degeneration (SVD); Wagner syndrome 1 (WGN1); Knobloch syndrome (KNO); Enhanced S-cone syndrome (ESCS); Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
  • Polymicrogyria; Bilateral frontal polymicrogyria (BFP); Bilateral frontoparietal polymicrogyria (BFPP); Bilateral perisylvian polymicrogyria (BPP); Bilateral parasagittal parieto-occipital polymicrogyria (BPOP); Bilateral generalised polymicrogyria (BGP); Unilateral Polymicrogyria (ULP)
DNM2 dynamin 2
  • Toll Like Receptor 4 (TLR4) Cascade
  • Retrograde neurotrophin signalling
  • Gap junction degradation
  • Formation of annular gap junctions
  • NOSTRIN mediated eNOS trafficking
  • MHC class II antigen presentation
  • Lysosome Vesicle Biogenesis
  • Golgi Associated Vesicle Biogenesis
  • Recycling pathway of L1
  • Clathrin-mediated endocytosis
  • NGF-stimulated transcription
  • Centronuclear myopathy
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
ITGB3 integrin subunit beta 3
  • Platelet degranulation
  • Elastic fibre formation
  • PECAM1 interactions
  • Molecules associated with elastic fibres
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Syndecan interactions
  • Syndecan interactions
  • ECM proteoglycans
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Abciximab
  • Eptifibatide
  • Antithymocyte immunoglobulin (rabbit)
  • Levothyroxine
  • Tirofiban
  • Resveratrol
  • Lefradafiban
  • LM-609
  • Fradafiban
  • Ferric maltol
  • Glanzmann thrombasthenia
  • Allograft rejection
PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Costimulation by the CD28 family
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • FLT3 Signaling
  • STAT5 Activation
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Dodecyltrimethylammonium
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Metachondromatosis
STAT1 signal transducer and activator of transcription 1
  • Interleukin-6 signaling
  • ISG15 antiviral mechanism
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Regulation of RUNX2 expression and activity
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
  • IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency
CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Congenital generalized lipodystrophy (CGL)
CBL Cbl proto-oncogene
  • Interleukin-6 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Spry regulation of FGF signaling
  • Regulation of KIT signaling
  • EGFR downregulation
  • TGF-beta receptor signaling activates SMADs
  • Constitutive Signaling by EGFRvIII
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Negative regulation of MET activity
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Negative regulation of FLT3
  • FLT3 signaling by CBL mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
FLT4 fms related receptor tyrosine kinase 4
  • VEGF binds to VEGFR leading to receptor dimerization
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Sorafenib
  • Sunitinib
  • Vatalanib
  • TG-100801
  • Denibulin
  • ABT-869
  • IMC-1C11
  • Pazopanib
  • Axitinib
  • Regorafenib
  • Lenvatinib
  • Nintedanib
  • Fostamatinib
  • Selpercatinib
  • Lymphedemas, including: Lymphedema, hereditary I; Lymphedema-distichiasis syndrome (LD); Hypotrichosis-lymphedema-telangiectasia syndrome (HLTS)
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
SYNGAP1 synaptic Ras GTPase activating protein 1
  • Regulation of RAS by GAPs
  • Non-syndromic autosomal dominant mental retardation

Page 1 out of 4 pages